PHARPharming Group N.V.
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~1% a year FCF growth. The price demands less than its three-year revenue growth of 22% a year, expectations look modest.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What PHAR's price assumes
Today's price asks for 1.3% free cash flow growth a year; over the last three years Pharming Group N.V. delivered +37%, so the price asks for less than the record.
Price / sales · no trailing P/E on file: measured against sales instead
- Free cash flow yield
- 7.0%
Free cash flow yield · Biotechnology median 4.3%
- Growth the price implies
- +1.3%
Growth the price implies · The price pays for +1.3% free cash flow growth a year for a decade; the business has delivered +37% a year over the last three.
- Price / book
- 4.37
Price / book · as of 2026-Q1
Details›
- Price / bookas of 2026-Q1
- 4.37
- EV / EBITas of 2026-Q1
- 57.7
- EV / salesas of 2026-Q1
- 3.35
- Free cash flow, trailing twelve months
- $54M
- Market capitalisation70.2 million shares, counted Dec 31, 2025
- $777M
- 3-year revenue growth
- +22%
- 3-year free cash flow growth
- +37%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.